

HIV Health Outcomes: It's More Than Just Viral Suppression

Although people with HIV (PWH) in the United States (US) are now less likely to die of HIV-specific causes compared to past years, they are burdened with more chronic diseases and attendant mortality than HIV uninfected persons.¹⁻⁴







The purpose of this resource is to increase clinician awareness of the increased prevalence of specific illnesses and mortalities among PWH in the US, with recommendations for prevention, screening, and harm reduction.

These include:

- Specific non-AIDS defining malignancies (anal, bronchopulmonary, and oropharyngeal cancers); and cervical cancer
- Atherosclerotic cardiovascular disease
- Behavioral/mental health conditions (e.g., depression, anxiety, substance use)

This document is not intended to be an all-inclusive list of all-cause mortality among PWH in the US.



DISEASE	RELATIVE RATES IN PWH	SCREENING
 Anal Cancer	Up to 80x more common	Annual DARE and anal Pap for MSM and transgender women > 35 years, and other individuals > 45 years
 Bronchopulmonary Cancer	48% more common	Annual low-dose computed tomography (LDCT) scan for those aged 50-80 years with a smoking history of ≥20-pack-years and who currently smoke or quit within past 15 years
 Cervical Cancer	3-4x more common	Cervical Pap test at diagnosis. See page 2 for subsequent recommendations
 Dental/Oropharyngeal Cancers (OPC)	3x more common	Dental/oral health exam every 6 months
 Atherosclerotic Cardiovascular Disease (ASCVD)	2x more likely	Annual ASCVD 10-year risk calculator for those aged 20-79 years
 Mental Health (MHD) and Substance Use (SUD) Disorders	MHD almost 2x more common SUD 4X more common	Annual screening for depression, anxiety, post-traumatic stress, alcohol/substance use disorders including tobacco smoking

Cancers: Risk Reduction and Screening

Antiretroviral therapy (ART) should be initiated as soon as possible after HIV diagnosis. ART with sustained viral suppression is strongly linked to lower incidence of premature mortality among people with HIV (PWH). This recommendation will not be repeated in Risk Reduction recommendations below.

Anal Cancer

- **80 times more common** in men who have sex with men (MSM) with HIV than in MSM without HIV.⁵ The rates of anal cancer among women with HIV and men with HIV who have sex with women (MSW) are lower, but higher than the rate among the general population,⁶ and the rate of anal dysplasia among transgender women with HIV is similar to that of MSM with HIV.⁷
- **Risk Reduction:**
 - > **Human papillomavirus (HPV) vaccination** if ≤ 26 years old⁸
 - > Shared decision-making for completing HPV vaccination of those 27-45 years old⁸
 - > Smoking cessation counseling, support, medications¹²
- **Screening:**
 - > Annual symptom screening, perianal visual inspection, and digital anal rectal exam (**DARE**), for PWH of all genders ≥ 35 years old⁸
 - > For MSM and transgender women ≥ 35 years, and all other patients ≥ 45 years, and high-resolution anoscopy (HRA) is available, an annual **anal Pap test** with reflex HPV testing should be done. If Pap shows \geq low-grade intraepithelial lesion (LSIL), refer for **HRA**.¹⁵

Bronchopulmonary Cancers

- PWH have a **48% higher risk** of lung cancer compared to the general US population¹²
- **Risk Reduction:**
 - > Smoking cessation counseling, support, medications¹²
- **Screening:**
 - > Annual **low-dose computed tomography (LDCT)** in those aged 50-80 years who have ≥ 20 -pack-year (# cigs/day x # years smoked) smoking history and currently smoke or have quit within the past 15 years^{13,14}

Cervical Cancer

- **3-4 times more common** in cisgender women with HIV than in cisgender women without HIV¹⁶
- Anyone with a cervix is at risk of cervical cancer; this may include transgender men, and non-binary and intersex individuals. Screening should be based on age recommendations
- **Risk Reduction:**
 - > **HPV vaccination** if ≤ 26 years old⁸

Cervical Cancer, continued

- > Shared decision-making for completing HPV vaccination of those 27-45 years old⁸
- > Smoking cessation counseling, support, medications¹¹

Screening:⁸

- > Persons with an intact uterine cervix aged 21-29 years: **cervical Pap test** at the time of initial HIV diagnosis
 - If the initial Pap result is normal, repeat every 12 months. If the results of 3 consecutive annual Pap tests are normal, follow-up Pap tests every 3 years
 - For abnormal Pap results of atypical squamous cells of undetermined significance (ASCUS) or higher grade (LSIL or high-grade intraepithelial lesion [HSIL]), refer for **colposcopy**
- > Persons aged ≥ 30 years: **cervical Pap test (with reflex HPV test if available)** at the time of HIV diagnosis, then every 12 months for lifetime of the patient
 - Pap testing only: If the initial Pap result is normal, repeat every 12 months. If the results of 3 consecutive annual Pap tests are normal, follow-up Pap tests every 3 years
 - Pap and HPV co-testing: If both test results are negative, repeat screening in 3 years. If normal Pap but positive HPV test, repeat co-testing in 1 year (if HPV 16 or 18 positive, refer for colposcopy)
 - If \geq LSIL, or HPV test shows HPV 16 or 18 positive, refer for **colposcopy**
 - If ASCUS without positive HPV, then repeat the Pap test alone in 6-12 months or do Pap test with HPV test in 12 months, and refer for colposcopy if result is \geq ASCUS

Dental—Oropharyngeal Cancers (OPC)

- HPV-related and HPV-unrelated OPCs occur **3 times more frequently** among PWH than in the general US population^{8,18}
- **Risk Reduction:**
 - > **HPV vaccination** if ≤ 26 years old^{8,18}
 - > Shared decision-making for completing HPV vaccination of those 27-45 years old⁸
 - > Smoking cessation counseling, support, medications¹²
- **Screening:**
 - > **Dental exam at least once every 6 months** (regardless of dentition status) inclusive of thorough exam of head, neck, and oropharyngeal tissues

Everyone

- Remember routine screening for other common cancers that are not known to be elevated in PWH

Atherosclerotic Cardiovascular Disease (ASCVD): Risk Reduction and Screening

- Adults with HIV are **2 times more likely** to develop ASCVD compared to adults without HIV¹⁸
- **Risk Reduction:**
 - > **ART with sustained viral suppression** (because chronic HIV viremia and HIV-associated immunosuppression are associated with increased ASCVD risk)²⁰
 - > **Smoking cessation** counseling, support, medications¹²
 - > **Blood pressure (BP) control** (<130 mm Hg systolic and <80 mm Hg diastolic)²³
 - Reduction in dietary sodium
 - Increase in dietary potassium (unless contradicted by other conditions)
 - Reduction or elimination of medications or other substances (over-the-counter and illicit) that increase BP, or heart rate, or that can cause vasospasm²²
 - > **Alcohol use reduction** to ≤1 drink/day (14 g of alcohol) for women and ≤2 drinks/day for men²³
 - > **Changes in diet** (to plant-based or Mediterranean-like diet)²¹
 - > **Weight reduction** if overweight or obese (body mass index ≥25)^{21,22}
 - > Random or fasting glucose every 12 months for **diabetes mellitus (DM) screening**,²⁴ and glucose control for people who have DM
 - > 150 minutes/week of accumulated moderate-intensity **physical activity** or 75 minutes/week of vigorous-intensity physical activity²⁵
- **Prescribe statins to prevent cardiovascular events**
 - For patients ages 40–75 years with 10-year ASCVD risk estimates between 5 and 20%, prescribe at least moderate intensity statin therapy (pitavastatin 4mg, atorvastatin 20mg, or rosuvastatin 10mg)^{9,10}
 - For patients ages 40–75 years with 10-year ASCVD risk estimates less than 5%, consider initiating moderate intensity statin therapy, depending on the presence of HIV-related factors that can increase ASCVD risk¹⁰
 - Prescribe statins and other lipid lowering medications as recommended for the general population by the ACC/AHA Task Force on Clinical Practice Guidelines¹⁰
 - If patient is taking a boosted ART regimen (i.e., with ritonavir or cobicistat) be cautious of interactions with statins; generally, may use limited doses of atorvastatin or rosuvastatin¹⁹ (assess with drug-drug interaction checker)
- **Screening:**
 - > ACC/AHA ASCVD **10-year risk calculator** annually for persons aged 20–79 years
 - Although HIV infection has been identified as a risk factor for ASCVD, it is not integrated into the calculator algorithm,²⁰ and the actual 10-year risk may be underestimated

Mental Health Disorders and Related Problems: Risk Reduction and Screening

- Adults with HIV are nearly **2 times more likely** of being diagnosed with a mental illness compared to adults without HIV infection²⁶
- Past-year non-prescribed substance use is **4 times more likely** in adults with HIV²⁷
- Mental health problems are associated with mortality through their link to suicide, overdose, fatal injury, and end-stage organ damage
- **Risk Reduction:**
 - > Provide naloxone to people who use opioids to prevent overdose
 - > Inform patients about the 988 National Suicide and Crisis Lifeline that can be called or texted 24/7
 - > Use local and national resources to help incorporate behavioral health screening, referral, or treatment into primary HIV care:
 - Implementing Substance Use Disorder (SUD) Services in HIV Care Settings Toolkit:
<https://aidsetc.org/resource/sud-toolkit>

References

1. Buchacz K, Armon C, Palella FJ Jr, et al. The HIV Outpatient Study-25 Years of HIV Patient Care and Epidemiologic Research. *Open Forum Infect Dis*. 2020;7(5):ofaa123. Published 2020 Apr 11.
2. Bosh KA, Johnson AS, Hernandez AL, et al. Vital Signs: Deaths Among Persons with Diagnosed HIV Infection, United States, 2010–2018. *MMWR Morb Mortal Wkly Rep* 2020;69:1717–1724.
3. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. *N Engl J Med*. 2009;360(18):1815–1826.
4. CDC HIV cohort, HIV Outpatient Study (HOPS); Edwards JK, Cole SR, Breger TL, et al. Mortality among persons entering HIV care compared with the general U.S. population: An observational study. *Ann Intern Med*. 2021;174(9):1197–1206.
5. ANCHOR Study. Anal Cancer Risks Compared. Accessed 12/28/22. <https://anchorstudy.org/anal-cancer-risk-among-hiv-positive-men-and-women>
6. Clifford GM, Georges D, Shiels MS, et al. A meta-analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale. *Int J Cancer*. 2021;148(1):38–47.
7. Kobayashi T, Sigel K, Gaisa M. Prevalence of Anal Dysplasia in Human Immunodeficiency Virus-Infected Transgender Women. *Sex Transm Dis*. 2017 Nov;44(11):714–716.
8. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Human Papillomavirus Disease. July 9, 2024. Accessed 8/16/2024. <https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/human-0>.
9. Grinspoon SK, Fitch KV, Zanni MV, et al. Pitavastatin to Prevent Cardiovascular Disease in HIV Infection. *N Engl J Med*. 2023 Aug 24;389(8):687–699.
10. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Statin Therapy in People with HIV. February 27, 2024. Accessed 8/16/2024. <https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv-statin-therapy-people-hiv?view=full>
11. Haas CB, Engels EA, Horner MJ, et al. Trends and risk of lung cancer among people living with HIV in the USA: a population-based registry linkage study. *Lancet HIV*. 2022 Oct;9(10):e700–e708.
12. Ranjit S, Kumar S. Recent advances in cancer outcomes in HIV-positive smokers. *F1000Res*. 2018 Jun 11;7:F1000 Faculty Rev-718. doi: 10.12688/f1000research.12068.1.
13. USPSTF. Lung Cancer: Screening. March 9, 2021. <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening>. Accessed 12/29/22.
14. American Cancer Society. Lung Cancer Screening Guidelines. <https://www.cancer.org/health-care-professionals/american-cancer-society-prevention-early-detection-guidelines/lung-cancer-screening-guidelines.html>. Accessed 12/29/22.
15. Stier EA, Clarke MA, Deshmukh AA, et al. International Anal Neoplasia Society's consensus guidelines for anal cancer screening. *Int J Cancer*. 2024; 154(10): 1694–1702.
16. Stier EA, Engels E, Horner MJ, et al. Cervical cancer incidence stratified by age in women with HIV compared with the general population in the United States, 2002–2016. *AIDS*. 2021 Sep 1;35(11):1851–1856. doi: 10.1097/QAD.0000000000002962. PMID: 34049357; PMCID: PMC8373779.
17. Beachler DC, Abraham AG, Silverberg MJ et al (2014). Incidence and risk factors of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma in HIV-infected individuals. *Oral Oncol* 50: 1169–1176.
18. Kaczmarczyk KH, Yusuf H. The impact of HPV vaccination on the prevention of oropharyngeal cancer: A scoping review. *Community Dent Health*. 2022;39(1):14–21.
19. Shah ASV, Stelzle D, Lee KK, et al. Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV: Systematic Review and Meta-Analysis. *Circulation*. 2018 Sep 11;138(11):1100–1112.
20. Feinstein MJ, Hsue PY, Benjamin LA, et al. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association. *Circulation*. 2019 Jul 9;140(2):e98–e124.
21. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2019 Jun 25;73(24):e285–e350. Erratum in: *J Am Coll Cardiol*. 2019 Jun 25;73(24):3237–3241. <https://pubmed.ncbi.nlm.nih.gov/30423391/>
22. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. et al. *Hypertension*. 2018 Jun;71(6):e13–e115. Erratum in: *Hypertension*. 2018 Jun;71(6):e140–e144.
23. U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary Guidelines for Americans, 2020–2025. 9th Edition. December 2020. Available at [DietaryGuidelines.gov](https://www.dietaryguidelines.gov).
24. Thompson MA, Horberg MA, Agwu AL, et al. Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America, *Clinical Infectious Diseases*, Volume 73, Issue 11, 1 December 2021, Pages e3572–e3605, <https://doi.org/10.1093/cid/ciaa1391>. Accessed 7/14/23.
25. U.S. Department of Health and Human Services. Physical Activity Guidelines for Americans, 2nd edition. Washington, DC: U.S. Department of Health and Human Services; 2018.
26. Gooden TE, Gardner M, Wang J, et al. The risk of mental illness in people living with HIV in the UK: a propensity score-matched cohort study. *Lancet HIV*. 2022;9(3):e172–e181.
27. Shiau S, Arpadi SM, Yin MT, Martins SS. Patterns of drug use and HIV infection among adults in a nationally representative sample. *Addict Behav*. 2017 May;68:39–44. <https://doi.org/10.1016/j.addbeh.2017.01.015>. Epub 2017 Jan 7.